ACOR Acorda Therapeutics Inc

Price (delayed)

$10.17

Market cap

$12.63M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.51

Enterprise value

$165.14M

Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA® (levodopa inhalation powder) is approved for intermittent treatment of OFF episodes in adults ...

Highlights

The company's EPS has surged by 99% YoY and by 73% QoQ

ACOR's net income has soared by 85% YoY and by 24% QoQ

Acorda Therapeutics's debt has decreased by 4% YoY but it has increased by 2.5% QoQ

ACOR's quick ratio is down by 25% from the previous quarter and by 16% YoY

The company's equity fell by 22% YoY and by 13% QoQ

Sector: Healthcare

Industry: Biotechnology

Website: http://www.acorda.com

Peers: RGEN BMRN CHRS

Key stats

What are the main financial stats of ACOR

Market

Shares outstanding

1.24M

Market cap

$12.63M

Enterprise value

$165.14M

Valuations

Price to earnings (P/E)

N/A

Price to book (P/B)

0.21

Price to sales (P/S)

0.11

EV/EBIT

13.26

EV/EBITDA

3.74

EV/Sales

1.49

Earnings

Revenue

$111.12M

EBIT

$12.45M

EBITDA

$44.18M

Free cash flow

-$2.12M

Per share

EPS

-$1.51

Free cash flow per share

-$1.71

Book value per share

$47.47

Revenue per share

$89.47

TBVPS

$67.9

Balance sheet

Total assets

$366.34M

Total liabilities

$307.39M

Debt

$186.09M

Equity

$58.96M

Working capital

$27.43M

Liquidity

Debt to equity

3.16

Current ratio

1.59

Quick ratio

0.98

Net debt/EBITDA

3.45

Margins

EBITDA margin

39.8%

Gross margin

87.2%

Net margin

-14.4%

Operating margin

-18.4%

Efficiency

Return on assets

-4.2%

Return on equity

-21.5%

Return on invested capital

6.6%

Return on capital employed

3.9%

Return on sales

11.2%

Dividend

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

ACOR stock price

How has the Acorda Therapeutics stock price performed over time

Intraday

-3.05%

1 week

2.73%

1 month

6.38%

1 year

1,546.96%

YTD

1,226.46%

QTD

-32.15%

Financial performance

How have Acorda Therapeutics's revenue and profit performed over time

Revenue

$111.12M

Gross profit

$96.87M

Operating income

-$20.43M

Net income

-$15.95M

Gross margin

87.2%

Net margin

-14.4%

ACOR's net income has soared by 85% YoY and by 24% QoQ

Acorda Therapeutics's net margin has surged by 83% YoY and by 20% QoQ

Acorda Therapeutics's operating income has surged by 60% YoY and by 8% QoQ

ACOR's operating margin has surged by 55% year-on-year and by 3.2% since the previous quarter

Growth

What is Acorda Therapeutics's growth rate over time

Valuation

What is Acorda Therapeutics stock price valuation

P/E

N/A

P/B

0.21

P/S

0.11

EV/EBIT

13.26

EV/EBITDA

3.74

EV/Sales

1.49

The company's EPS has surged by 99% YoY and by 73% QoQ

ACOR's P/B is 27% below its 5-year quarterly average of 0.3 but 10% above its last 4 quarters average of 0.2

The company's equity fell by 22% YoY and by 13% QoQ

ACOR's price to sales (P/S) is 70% lower than its 5-year quarterly average of 0.4 but 20% higher than its last 4 quarters average of 0.1

The company's revenue fell by 10% YoY and by 5% QoQ

Efficiency

How efficient is Acorda Therapeutics business performance

The company's return on sales has surged by 130% YoY and by 38% QoQ

ACOR's ROIC has soared by 128% year-on-year and by 32% since the previous quarter

Acorda Therapeutics's ROA has soared by 83% YoY and by 24% from the previous quarter

Acorda Therapeutics's ROE has soared by 77% YoY and by 19% from the previous quarter

Dividends

What is ACOR's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for ACOR.

Financial health

How did Acorda Therapeutics financials performed over time

ACOR's total assets is 19% greater than its total liabilities

Acorda Therapeutics's current ratio has decreased by 26% QoQ and by 7% YoY

ACOR's quick ratio is down by 25% from the previous quarter and by 16% YoY

Acorda Therapeutics's debt to equity has increased by 23% YoY and by 18% from the previous quarter

The company's equity fell by 22% YoY and by 13% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.